Physician profile
Anil Potti
NPI 1427122266
$6,087.71
in general payments reported to CMS, 2019-2025
73 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $460 · 2021: $920 · 2022: $915 · 2023: $1,005 · 2024: $982 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,094.77 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $599.37 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Biotech, INC. | $354.35 | 2019-2025 | Erleada, Darzalex, Akeega |
| Pfizer INC. | $344.45 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $275.27 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astellas Pharma US INC | $269.52 | 2019-2025 | Xospata, Vyloy, Xtandi |
| Novartis Pharmaceuticals Corporation | $215.39 | 2019-2025 | |
| Eisai INC. | $202.16 | 2020-2025 | |
| Exelixis INC. | $201.26 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $200.77 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $189.49 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
| Myriad Genetic Laboratories, INC. | $173.17 | 2021-2024 | Precisetumor, Myrisk |
| Amgen INC. | $158.23 | 2019-2021 | |
| Seagen INC. | $157.33 | 2019-2023 | Padcev |
| Lilly USA, LLC | $154.79 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Glaxosmithkline, LLC. | $136.20 | 2020-2025 | Ojjaara |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Potti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.